Takeda and Millennium Termination of Ganitumab Phase III Study in Metastatic Pancreatic Cancer in Japan
10:30 EDT 9 Aug 2012 | Drugs.com
OSAKA, Japan, and CAMBRIDGE, Mass, August 9, 2012 – Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) and Millennium: .....
Original Article: Takeda and Millennium Termination of Ganitumab Phase III Study in Metastatic Pancreatic Cancer in Japan
More From BioPortfolio on "Takeda and Millennium Termination of Ganitumab Phase III Study in Metastatic Pancreatic Cancer in Japan"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
